You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Merck
Medtronic
Harvard Business School
Colorcon

Last Updated: February 22, 2024

OLINVYK Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Olinvyk patents expire, and what generic alternatives are available?

Olinvyk is a drug marketed by Trevena and is included in one NDA. There are four patents protecting this drug.

This drug has fifty-one patent family members in twenty-three countries.

The generic ingredient in OLINVYK is oliceridine. One supplier is listed for this compound. Additional details are available on the oliceridine profile page.

DrugPatentWatch® Generic Entry Outlook for Olinvyk

Olinvyk will be eligible for patent challenges on October 30, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 23, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for OLINVYK
International Patents:51
US Patents:4
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 32
Patent Applications: 56
Drug Prices: Drug price information for OLINVYK
What excipients (inactive ingredients) are in OLINVYK?OLINVYK excipients list
DailyMed Link:OLINVYK at DailyMed
Drug patent expirations by year for OLINVYK
Drug Prices for OLINVYK

See drug prices for OLINVYK

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for OLINVYK
Generic Entry Date for OLINVYK*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for OLINVYK

US Patents and Regulatory Information for OLINVYK

OLINVYK is protected by four US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of OLINVYK is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting OLINVYK

Opioid receptor ligands and methods of using and making same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION

Opioid receptor ligands and methods of using and making same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION

Opioid receptor ligands and methods of using and making same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION

Opioid receptor ligands and methods of using and making same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION

FDA Regulatory Exclusivity protecting OLINVYK

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-001 Oct 30, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-002 Oct 30, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-001 Oct 30, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-003 Oct 30, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-002 Oct 30, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-003 Oct 30, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for OLINVYK

When does loss-of-exclusivity occur for OLINVYK?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 12230761
Estimated Expiration: ⤷  Try a Trial

Patent: 17200745
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 2013024136
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 30742
Estimated Expiration: ⤷  Try a Trial

China

Patent: 3702561
Estimated Expiration: ⤷  Try a Trial

Croatia

Patent: 0171021
Estimated Expiration: ⤷  Try a Trial

Cyprus

Patent: 19057
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 88403
Estimated Expiration: ⤷  Try a Trial

Patent: 90415
Estimated Expiration: ⤷  Try a Trial

Eurasian Patent Organization

Patent: 5456
Estimated Expiration: ⤷  Try a Trial

Patent: 1391332
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 88403
Estimated Expiration: ⤷  Try a Trial

Patent: 90415
Estimated Expiration: ⤷  Try a Trial

Patent: 72076
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 50984
Estimated Expiration: ⤷  Try a Trial

Hungary

Patent: 32948
Estimated Expiration: ⤷  Try a Trial

Patent: 54055
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 8506
Estimated Expiration: ⤷  Try a Trial

Patent: 3318
Estimated Expiration: ⤷  Try a Trial

Patent: 2165
Estimated Expiration: ⤷  Try a Trial

Patent: 4407
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 12169
Estimated Expiration: ⤷  Try a Trial

Patent: 43949
Estimated Expiration: ⤷  Try a Trial

Patent: 49341
Estimated Expiration: ⤷  Try a Trial

Patent: 23683
Estimated Expiration: ⤷  Try a Trial

Patent: 48750
Estimated Expiration: ⤷  Try a Trial

Patent: 14508811
Estimated Expiration: ⤷  Try a Trial

Patent: 16155843
Estimated Expiration: ⤷  Try a Trial

Patent: 18048193
Estimated Expiration: ⤷  Try a Trial

Patent: 20073570
Estimated Expiration: ⤷  Try a Trial

Patent: 21176885
Estimated Expiration: ⤷  Try a Trial

Patent: 23075282
Estimated Expiration: ⤷  Try a Trial

Lithuania

Patent: 88403
Estimated Expiration: ⤷  Try a Trial

Montenegro

Patent: 754
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 5993
Estimated Expiration: ⤷  Try a Trial

Patent: 3143
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 88403
Estimated Expiration: ⤷  Try a Trial

Patent: 90415
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 88403
Estimated Expiration: ⤷  Try a Trial

Patent: 90415
Estimated Expiration: ⤷  Try a Trial

Serbia

Patent: 111
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 88403
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 1991326
Estimated Expiration: ⤷  Try a Trial

Patent: 1991327
Estimated Expiration: ⤷  Try a Trial

Patent: 2129247
Estimated Expiration: ⤷  Try a Trial

Patent: 140047599
Estimated Expiration: ⤷  Try a Trial

Patent: 180100453
Estimated Expiration: ⤷  Try a Trial

Patent: 190072665
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 32009
Estimated Expiration: ⤷  Try a Trial

Patent: 57549
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OLINVYK around the world.

Country Patent Number Title Estimated Expiration
Japan 6649341 ⤷  Try a Trial
Poland 3290415 ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2012129495 ⤷  Try a Trial
Japan 2016155843 オピオイド受容体リガンド並びにそれらの使用方法及び製造方法 (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING THE SAME) ⤷  Try a Trial
Hungary E054055 ⤷  Try a Trial
Australia 2012230761 Opioid receptor ligands and methods of using and making same ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Johnson and Johnson
McKinsey
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.